文献速递临床试验与 GCP流行病学与生物统计

VATS与开胸肺叶切除术治疗肺癌的生存结局:随机试验个体患者数据荟萃分析

Survival outcome of VATS compared with open lobectomy for lung cancer: an individual patient data meta-analysis of randomised trials.
PubMed 文献 · Lancet · 2026-01-01

该研究系统检索2000年至2025年随机对照试验,纳入3项研究共1185例早期非小细胞肺癌患者,比较电视辅助胸腔镜手术(VATS)与开胸肺叶切除术的生存结局。

要点

  • 技术可行时,VATS应优先作为早期非小细胞肺癌手术切除的入路选择。

核心结论

  • VATS肺叶切除术较开胸手术改善总生存,且不损害无病生存。
  • 技术可行时,VATS应优先作为早期非小细胞肺癌手术切除的入路选择。

研究设计与样本

  • 系统检索PubMed、MEDLINE、Embase和Cochrane Central Register of Controlled Trials,限2000年1月1日至2025年6月13日发表的论文。
  • 纳入比较VATS与开胸肺叶切除术的已完成随机对照试验,对象为18岁及以上临床早期非小细胞肺癌成人,且收集死亡和疾病复发信息。
  • 提取个体患者数据,数据不可用时联系作者;主要分析采用一阶段随机效应Cox比例风险模型,并采用两阶段方法评估一致性。
  • 共筛选554篇文章,3项研究符合纳入标准,提供1185例患者数据(VATS组586例,开胸组599例)。
  • 使用Cochrane随机试验偏倚风险工具评估偏倚风险;主要结局为总生存,次要结局为无病生存。

主要发现

  • 两项结局均无统计学异质性证据。

临床怎么用

  • 对于临床早期非小细胞肺癌成人患者,当技术可行时,应优先选择VATS肺叶切除术作为手术入路。
  • VATS的选择不应仅基于非肿瘤学获益,其总生存优势应纳入临床决策。

局限性

  • 仅纳入3项随机对照试验,样本量共1185例,证据基础有限。
  • 原文未报告各试验具体偏倚风险评分及详细局限性描述。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Video-assisted thoracoscopic surgery (VATS) is currently the most common approach for pulmonary lobectomy in early-stage lung cancer. Reported advantages include less pain, fewer complications, faster recovery, and improved postoperative quality of life. The widespread adoption of VATS lobectomy is principally based on non-oncological benefits. Its oncological equivalence to open surgery remains assumed as no single trial has been powered for survival. To address this important question, we sought to conduct an individual patient data meta-analysis of eligible randomised trials. METHODS: We systematically reviewed PubMed, MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials, limiting the searches to papers published between Jan 1, 2000, and June 13, 2025. We included completed randomised controlled trials comparing VATS versus open lobectomy performed after the year 2000 conducted for clinical early-stage non-small-cell lung cancer in adults aged 18 years or older that collected information on mortality and disease recurrence. Individual patient data were extracted from the included studies, and authors were contacted where data were unavailable. The primary outcome was overall survival, and the secondary outcome was disease-free survival. Risk of bias was assessed using the Cochrane risk of bias tool for randomised trials. The primary analytical strategy was a one-stage random effects Cox proportional hazards model. A two-stage approach was performed to assess consistency. FINDINGS: We screened 554 articles and three studies were eligible for inclusion. Data were provided for 1185 patients (586 randomised to VATS and 599 randomised to open lobectomy). Overall survival favoured VATS lobectomy, reflecting a 21% mortality risk reduction (pooled hazard ratio [HR] 0·79 [95% CI 0·65-0·96]). Disease-free survival was similar in both groups (pooled HR 0·91 [0·75-1·12]). There was no evidence of statistical heterogeneity across trials for either outcome. INTERPRETATION: This meta-analysis provides evidence that surgical access by VATS lobectomy improved overall survival compared with open surgery without any compromise to disease-free survival. These results underscore the importance of prioritising VATS when technically feasible as the access of choice for surgical resection of early-stage non-small-cell lung cancer. FUNDING: National Institute for Health and Care Research.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Harris RA, Law JJ, Hao L, et al. Survival outcome of VATS compared with open lobectomy for lung cancer: an individual patient data meta-analysis of randomised trials. Lancet. 2026. PMID: 41864749. doi:10.1016/S0140-6736(26)00031-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。